Precision BioSciences, Novartis Launch Up-to-$1.5B In Vivo Genome Editing Collaboration.
Human gene therapy, 33(15-16): 777-779 PMID 35972327 DOI 10.1089/hum.2022.29214.bfs
Abstract
This article has no abstract in PubMed.
Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.